A Study Of Senyo Health With Comorbid Alcohol Use Disorder Treatment In Bipolar Patients
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
The purpose of this study is to examine the effectiveness of a digital integrated behavioral health (IBH) platform in improving substance use outcomes, including treatment retention and substance use frequency and severity in patients with Bipolar Disorder.
Eligibility criteria
Qualifiers
History of bipolar I disorder, bipolar II disorder, or schizoaffective disorder of the bipolar type
Alcohol use disorder.
Ability to read, write, and understand English;
Minimum DAST (1+) or AUDIT-C score (3+)
Disqualifiers
Diagnosed personality pathology as the primary presenting concern based on clinical judgment, severe cognitive impairment (e.g., intellectual disability or dementia), or psychosis;
Inability to actively participate in and learn from psychotherapeutic interaction based on clinical evaluation and clinical judgment;
Needing a higher level of mental health care as demonstrated by ASAM[36] assessment;
Decline to answer suicidality questions;
Trial design
Treatments tested in this trial
- Senyo Health App
Treatment groups
40 Participants
are divided into 1 treatment groupLocations
1Mayo Clinic in Rochester55905, RochesterMinnesota, United States
Sponsors and collaborators
Mayo Clinic
Lead sponsor
Source ClinicalTrials.gov